TEX19 was also required to drive cell proliferation in a range of cancer cell types, and its expression was linked to a poor prognosis for breast cancer, kidney cancer, prostate cancer, and glioma cancer (Planells-Palop et al., 2017). Here, TEX19 is linked to prostate carcinoma.